Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Referral and Consultation | 5 | 2023 | 3579 | 0.920 |
Why?
|
Oncology Service, Hospital | 2 | 2017 | 57 | 0.680 |
Why?
|
Carcinoma, Lobular | 2 | 2020 | 488 | 0.600 |
Why?
|
Abdominal Neoplasms | 1 | 2019 | 286 | 0.570 |
Why?
|
Physician Assistants | 1 | 2018 | 188 | 0.520 |
Why?
|
Breast Neoplasms | 18 | 2023 | 20992 | 0.520 |
Why?
|
Mammography | 12 | 2018 | 2424 | 0.500 |
Why?
|
Radiology | 4 | 2023 | 2101 | 0.440 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1051 | 0.430 |
Why?
|
Fibrocystic Breast Disease | 5 | 2000 | 103 | 0.420 |
Why?
|
Tomography, X-Ray Computed | 13 | 2023 | 20499 | 0.410 |
Why?
|
Biopsy, Needle | 8 | 2000 | 1627 | 0.370 |
Why?
|
Academic Medical Centers | 5 | 2023 | 2742 | 0.360 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 1402 | 0.320 |
Why?
|
Breast | 8 | 2000 | 1961 | 0.310 |
Why?
|
Cancer Care Facilities | 2 | 2018 | 419 | 0.290 |
Why?
|
Radiology Information Systems | 3 | 2021 | 528 | 0.290 |
Why?
|
Inflammatory Breast Neoplasms | 2 | 2020 | 146 | 0.290 |
Why?
|
Lymphoma, T-Cell | 1 | 2009 | 304 | 0.280 |
Why?
|
Medical Oncology | 1 | 2018 | 2308 | 0.270 |
Why?
|
Liver Neoplasms | 2 | 2020 | 4314 | 0.270 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 4886 | 0.250 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3670 | 0.250 |
Why?
|
Radiology Department, Hospital | 2 | 2019 | 405 | 0.220 |
Why?
|
Ultrasonography, Mammary | 5 | 2018 | 239 | 0.210 |
Why?
|
Magnetic Resonance Imaging | 7 | 2021 | 36270 | 0.210 |
Why?
|
Genes, erbB-2 | 2 | 2014 | 162 | 0.200 |
Why?
|
Carcinoma, Ductal, Breast | 5 | 2020 | 1096 | 0.190 |
Why?
|
Stereotaxic Techniques | 5 | 2000 | 549 | 0.190 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2020 | 2004 | 0.180 |
Why?
|
Forms and Records Control | 1 | 2020 | 158 | 0.160 |
Why?
|
Incidental Findings | 2 | 2020 | 693 | 0.150 |
Why?
|
Calcinosis | 5 | 2000 | 1467 | 0.150 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2020 | 167 | 0.150 |
Why?
|
Calcium Phosphates | 1 | 2018 | 171 | 0.140 |
Why?
|
Surgical Instruments | 1 | 1999 | 382 | 0.140 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2020 | 270 | 0.140 |
Why?
|
Workload | 1 | 2002 | 845 | 0.140 |
Why?
|
Retrospective Studies | 18 | 2023 | 79984 | 0.140 |
Why?
|
Environment | 1 | 2002 | 1117 | 0.140 |
Why?
|
Tumor Burden | 2 | 2014 | 1886 | 0.140 |
Why?
|
Lung Neoplasms | 6 | 2020 | 13268 | 0.130 |
Why?
|
Neoplasms | 5 | 2017 | 21986 | 0.130 |
Why?
|
Quality Improvement | 3 | 2020 | 3793 | 0.130 |
Why?
|
Foreign Bodies | 1 | 1999 | 397 | 0.120 |
Why?
|
Immunoconjugates | 1 | 2023 | 949 | 0.120 |
Why?
|
Seat Belts | 1 | 1995 | 60 | 0.120 |
Why?
|
Humans | 50 | 2023 | 757566 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2020 | 906 | 0.120 |
Why?
|
Positron-Emission Tomography | 4 | 2017 | 6457 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2017 | 9245 | 0.120 |
Why?
|
Receptors, Progesterone | 2 | 2020 | 1129 | 0.120 |
Why?
|
Female | 37 | 2023 | 389943 | 0.110 |
Why?
|
Terminology as Topic | 1 | 2020 | 1533 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2018 | 1436 | 0.100 |
Why?
|
Radiopharmaceuticals | 2 | 2020 | 2634 | 0.100 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1999 | 935 | 0.100 |
Why?
|
Receptor, erbB-2 | 3 | 2023 | 2552 | 0.100 |
Why?
|
Receptors, Estrogen | 2 | 2020 | 2208 | 0.090 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 765 | 0.090 |
Why?
|
Interprofessional Relations | 1 | 2017 | 989 | 0.090 |
Why?
|
Mucous Membrane | 1 | 2013 | 657 | 0.090 |
Why?
|
Quinazolines | 2 | 2014 | 1371 | 0.090 |
Why?
|
Breast Diseases | 3 | 1998 | 443 | 0.090 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2009 | 40 | 0.080 |
Why?
|
Pleural Neoplasms | 1 | 2014 | 609 | 0.080 |
Why?
|
Prognosis | 4 | 2019 | 29488 | 0.080 |
Why?
|
Accidents, Traffic | 1 | 1995 | 815 | 0.080 |
Why?
|
Survival Analysis | 2 | 2019 | 10075 | 0.080 |
Why?
|
Contrast Media | 3 | 2018 | 5297 | 0.080 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2009 | 164 | 0.080 |
Why?
|
Neoplasm Staging | 7 | 2020 | 11082 | 0.080 |
Why?
|
Pulmonary Embolism | 2 | 2012 | 2540 | 0.080 |
Why?
|
Middle Aged | 25 | 2020 | 219192 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 932 | 0.070 |
Why?
|
Aged | 21 | 2020 | 167890 | 0.070 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2009 | 167 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39020 | 0.070 |
Why?
|
Nose Neoplasms | 1 | 2009 | 249 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2017 | 1991 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2014 | 1377 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1415 | 0.070 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2010 | 471 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 916 | 0.070 |
Why?
|
Adult | 21 | 2020 | 219725 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2796 | 0.060 |
Why?
|
Melanoma | 2 | 2014 | 5689 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1999 | 3432 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 2006 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 5272 | 0.060 |
Why?
|
Carcinoma in Situ | 2 | 2000 | 793 | 0.060 |
Why?
|
Aged, 80 and over | 9 | 2019 | 58558 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 11709 | 0.050 |
Why?
|
Radiation Injuries | 1 | 2010 | 1184 | 0.050 |
Why?
|
Boston | 3 | 2019 | 9298 | 0.050 |
Why?
|
Brachytherapy | 1 | 2010 | 1224 | 0.050 |
Why?
|
Mass Screening | 1 | 2018 | 5412 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4577 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2014 | 2524 | 0.050 |
Why?
|
Iohexol | 2 | 2014 | 204 | 0.050 |
Why?
|
Radiography | 2 | 2023 | 6956 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2023 | 8981 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12951 | 0.050 |
Why?
|
Camptothecin | 1 | 2023 | 589 | 0.040 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2005 | 615 | 0.040 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 13597 | 0.040 |
Why?
|
Medical Record Linkage | 1 | 2019 | 286 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 850 | 0.040 |
Why?
|
Radiographic Image Enhancement | 2 | 2014 | 875 | 0.040 |
Why?
|
Treatment Outcome | 7 | 2023 | 64242 | 0.040 |
Why?
|
Ultrasonography, Interventional | 2 | 2002 | 1487 | 0.040 |
Why?
|
Negotiating | 1 | 2018 | 148 | 0.040 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2012 | 4019 | 0.030 |
Why?
|
Radiographic Magnification | 1 | 1996 | 19 | 0.030 |
Why?
|
Male | 11 | 2017 | 358180 | 0.030 |
Why?
|
Fibroadenoma | 1 | 1996 | 41 | 0.030 |
Why?
|
Axilla | 1 | 2018 | 626 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.030 |
Why?
|
Fat Necrosis | 1 | 1995 | 60 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6323 | 0.030 |
Why?
|
Contusions | 1 | 1995 | 79 | 0.030 |
Why?
|
Risk | 2 | 2018 | 9590 | 0.030 |
Why?
|
Piperazines | 1 | 2005 | 2511 | 0.030 |
Why?
|
Radiography, Interventional | 2 | 1999 | 1112 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 1996 | 1628 | 0.030 |
Why?
|
Data Collection | 1 | 2002 | 3319 | 0.030 |
Why?
|
Pyrimidines | 1 | 2005 | 3005 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2014 | 281 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 546 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1277 | 0.030 |
Why?
|
Cysts | 1 | 1997 | 681 | 0.020 |
Why?
|
Vinblastine | 1 | 2013 | 488 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 6470 | 0.020 |
Why?
|
Markov Chains | 1 | 2014 | 965 | 0.020 |
Why?
|
Maytansine | 1 | 2011 | 86 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1996 | 1788 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 1996 | 972 | 0.020 |
Why?
|
Biopsy | 2 | 1999 | 6757 | 0.020 |
Why?
|
Mastectomy | 1 | 2018 | 1834 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3510 | 0.020 |
Why?
|
Ultrasonography | 2 | 2000 | 5951 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2009 | 5798 | 0.020 |
Why?
|
Estrogen Replacement Therapy | 1 | 1996 | 1206 | 0.020 |
Why?
|
Vacuum | 2 | 2000 | 65 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1087 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2809 | 0.020 |
Why?
|
Life Expectancy | 1 | 2014 | 1238 | 0.020 |
Why?
|
Risk Factors | 1 | 2014 | 73708 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54092 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2847 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2047 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4845 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2914 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2014 | 1957 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8815 | 0.020 |
Why?
|
Cohort Studies | 2 | 2023 | 41190 | 0.020 |
Why?
|
Decision Making | 1 | 2018 | 3909 | 0.010 |
Why?
|
Observer Variation | 1 | 2010 | 2599 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2370 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2638 | 0.010 |
Why?
|
Time Factors | 2 | 1996 | 39811 | 0.010 |
Why?
|
Outpatients | 1 | 2011 | 1590 | 0.010 |
Why?
|
Lymph Nodes | 1 | 1993 | 3470 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10749 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3524 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2002 | 25924 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5483 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10495 | 0.010 |
Why?
|
Biomedical Research | 1 | 2016 | 3415 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8426 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2014 | 3164 | 0.010 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1847 | 0.010 |
Why?
|
Benzamides | 1 | 2005 | 1363 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12047 | 0.010 |
Why?
|
Automation | 1 | 2000 | 581 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2014 | 5638 | 0.010 |
Why?
|
Age Factors | 1 | 2014 | 18326 | 0.010 |
Why?
|
Smoking | 1 | 2014 | 9036 | 0.010 |
Why?
|
Hyperplasia | 1 | 2000 | 1153 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 8946 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2010 | 4046 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 9163 | 0.010 |
Why?
|
Anticoagulants | 1 | 2012 | 4777 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20037 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 3415 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21217 | 0.010 |
Why?
|
Equipment Design | 1 | 2000 | 3502 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2000 | 3591 | 0.010 |
Why?
|
Lung | 1 | 2010 | 9973 | 0.010 |
Why?
|
Young Adult | 1 | 2011 | 58755 | 0.000 |
Why?
|
Case-Control Studies | 1 | 1997 | 22022 | 0.000 |
Why?
|
Adolescent | 1 | 2005 | 87819 | 0.000 |
Why?
|